CLINICAL TRIALS PROFILE FOR TELAPREVIR

505(b)(2) Clinical Trials for TELAPREVIR

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT01511432 ↗	A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects	Completed	Vertex Pharmaceuticals Incorporated	Phase 1	2012-01-01	The purpose of this study is to evaluate the relative bioavailability, safety, and tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets.

All Clinical Trials for TELAPREVIR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00336479 ↗	Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C	Completed	Vertex Pharmaceuticals Incorporated	Phase 2	2006-06-01	Study the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) and Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels
NCT00372385 ↗	Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C	Completed	Vertex Pharmaceuticals Incorporated	Phase 2	2006-08-01	Compare the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) with and without Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels
NCT00420784 ↗	A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)	Completed	Vertex Pharmaceuticals Incorporated	Phase 2	2007-02-01	The PROVE3 trial is a partially double blinded, randomized, Phase 2 research study of an investigational drug, Telaprevir (VX-950) or Placebo, with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a, Pegasys®), and Ribavirin (RBV, Copegus®) in people with genotype 1 hepatitis C who have not achieved a Sustained Viral Response (SVR) with a previous treatment of interferon therapy.
NCT00509210 ↗	Study of Telaprevir in Subjects With Hepatic Impairment	Completed	Vertex Pharmaceuticals Incorporated	Phase 1	2007-09-01	The purpose of this study is to assess the safety and pharmacokinetics of Telaprevir following administration of multiple oral doses to subjects with moderate and severe hepatic impairment.

Clinical Trial Conditions for TELAPREVIR

Condition Name

Condition Name for TELAPREVIR
Intervention	Trials
Hepatitis C	46
Hepatitis C, Chronic	16
Chronic Hepatitis C	10
HIV	7

Condition MeSH

Condition MeSH for TELAPREVIR
Intervention	Trials
Hepatitis C	89
Hepatitis	78
Hepatitis A	58
Hepatitis C, Chronic	43

Clinical Trial Locations for TELAPREVIR

Trials by Country

Trials by Country for TELAPREVIR
Location	Trials
United States	451
Canada	45
Japan	42
Germany	26
Spain	21

Trials by US State

Trials by US State for TELAPREVIR
Location	Trials
Texas	30
California	26
New York	26
Maryland	25
Florida	24

Clinical Trial Progress for TELAPREVIR

Clinical Trial Phase

Clinical Trial Phase for TELAPREVIR
Clinical Trial Phase	Trials
Phase 4	14
Phase 3	25
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for TELAPREVIR
Clinical Trial Phase	Trials
Completed	81
Terminated	11
Withdrawn	5

Clinical Trial Sponsors for TELAPREVIR

Sponsor Name

Sponsor Name for TELAPREVIR
Sponsor	Trials
Vertex Pharmaceuticals Incorporated	36
Tibotec BVBA	12
Bristol-Myers Squibb	6

Sponsor Type

Sponsor Type for TELAPREVIR
Sponsor	Trials
Industry	106
Other	94
NIH	7

Telaprevir: Clinical Trials Update, Market Analysis, and Projections

Last updated: February 21, 2026

What is the current status of telaprevir clinical development?

Telaprevir, a protease inhibitor developed by Vertex Pharmaceuticals, was approved by the U.S. Food and Drug Administration (FDA) in 2011 for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection. Clinical development for telaprevir has largely ceased for new indications. It was initially developed to be part of combination therapies for HCV, often paired with pegylated interferon alpha and ribavirin.

Key clinical trial milestones include:

• Phase 3 trials (e.g., PROVE 1, 2, 3) demonstrated high sustained virologic response (SVR) rates of around 75-80% when combined with interferon and ribavirin.
• The drug received approval based on trials showing improved effectiveness over previous standard of care.

Since 2014, Vertex has transitioned focus away from telaprevir, replaced by newer agents such as sofosbuvir and ledipasvir, which display better safety profiles and higher efficacy. No recent completion or initiation of trials for telaprevir are publicly reported.

What is the current market landscape for telaprevir?

Market saturation and obsolescence

Telaprevir's market presence has diminished substantially due to the advent of direct-acting antivirals (DAAs) that are all-oral, shorter in duration, and exhibit fewer adverse effects.

• In 2015, the global hepatitis C treatment market was valued at approximately USD 16 billion.
• The segment shifted significantly toward newer DAAs, reducing telaprevir's market share to negligible levels.

Competition and market share

New drugs such as sofosbuvir (Gilead Sciences), ledipasvir (Gilead), glecaprevir/pibrentasvir (AbbVie), and velpatasvir/sofosbuvir (Gilead) dominate treatment options, with market shares over 70% collectively.

• Telaprevir faced market exclusivity challenges since 2014.
• Gilead's Harvoni, approved in 2014, became the standard of care, rendering telaprevir largely obsolete in developed markets.

Patent status

Vertex’s patents for telaprevir expired in many jurisdictions by 2019, enabling biosimilar or generic competition, further diminishing its market relevance.

What are projections for telaprevir's future market and use?

Market outlook

• The market for telaprevir is expected to decline further, with minimal to no clinical use.
• Legacy treatments licensed before 2015 persist in some low-income markets, but the trend is toward fully generic regimens.

Regulatory and economic factors

• No new regulatory filings or clinical trials are expected for telaprevir.
• The decline aligns with global efforts to eliminate hepatitis C, which favor newer, more tolerable treatments.

Potential niche applications

• No evidence suggests continued or emerging niche uses for telaprevir.
• The focus remains on innovative DAAs with improved pharmacokinetics and lower resistance issues.

Summary of key data

Parameter	Data	Source
FDA approval date	May 2011	[1]
Peak global hepatitis C market value	USD 16 billion (2015)	[2]
Market share (2014-2015)	Dominated by Gilead's Harvoni and Sovaldi	[3]
Patent expiry	2019 in major jurisdictions	[4]
Current clinical trial activity	None reported since 2014	ClinicalTrials.gov

Key Takeaways

• Telaprevir was a significant hepatitis C treatment upon approval but has been phased out of clinical development.
• The market has shifted entirely to newer oral DAAs offering better safety and efficacy profiles.
• Patent expirations and the advent of generics have eliminated potential commercial opportunities.
• No active clinical development or regulatory interest exists for telaprevir.
• Legacy use persists mainly in low-resource settings, but the trend is toward standardization with newer agents.

FAQs

1. Why did telaprevir lose market relevance?
It was replaced by better-tolerated, orally administered DAAs with higher cure rates and fewer side effects.

2. Are there any ongoing clinical trials for telaprevir?
No. The last known phase 3 trials concluded by 2014; no new trials are scheduled or ongoing.

3. Can telaprevir be used outside approved indications?
Use outside approved indications is not recommended and lacks regulatory approval or clinical evidence.

4. What are the main competitors to telaprevir?
Gilead’s Harvoni (ledipasvir/sofosbuvir), Sovaldi (sofosbuvir), and AbbVie’s Mavyret (glecaprevir/pibrentasvir).

5. What is the outlook for hepatitis C treatment?
The trend is towards pan-genotypic, short-duration, oral regimens with high SVR rates, completely replacing older therapies like telaprevir.

---

References

[1] U.S. Food and Drug Administration. (2011). Telaprevir (Incivek) approval.
[2] MarketsandMarkets. (2015). Hepatitis C virus therapy market report.
[3] Gilead Sciences. (2014). Market reports on DAA therapies.
[4] European Patent Office. (2019). Patent expiry timelines for telaprevir.